The treatment is given as an intravenous infusion, which means it is delivered through a vein. The study looks at whether the new drug combination can help keep the cancer from coming back and whether it can remove all signs of invasive cancer in the breast and nearby lymph nodes before surgery. The course of the study includes treatment over a planned period, followed by surgery and later follow-up visits to monitor health over time.

Some medical terms used in the study include neoadjuvant, which means treatment given before surgery, and EFS, which means the length of time without a cancer-related event such as the cancer returning or worsening. The study also records side effects and overall health changes during follow-up.

The purpose of this study is to find out how many people in each treatment group have no remaining cancer or only a small amount in the breast and nearby lymph nodes after receiving the study treatment and before having surgery. The study will also look at how safe these treatments are, what side effects they may cause, and how they affect the body. Additionally, the study will examine whether participants are able to have surgery as planned and will follow participants over time to check if the cancer comes back and how long they survive.

Participants in this study will be randomly assigned to one of the treatment groups and will receive the study medicines for several months before having surgery to remove the cancer. During the study, participants will have regular visits where doctors will perform examinations, take blood samples, and do heart tests to check how the treatment is working and monitor for any side effects. Participants will also be asked to complete questionnaires about how they are feeling and any symptoms they may be experiencing. After surgery, participants will continue to be followed to see how well the treatment worked and to monitor their overall health.

Participants in the study will receive treatment with these medications for a short period before their scheduled surgery. The study will monitor how well the cancer responds to the treatment and will also keep track of any side effects that may occur. The trial aims to understand the effectiveness of these medications in shrinking the cancer and improving outcomes for patients with breast cancer.

Throughout the study, various assessments will be conducted, including imaging tests like MRI to evaluate the response of the cancer to the treatment. The study will also look at the overall survival and event-free survival of participants, which refers to the length of time patients live without the cancer returning or worsening. By exploring these treatments, the trial hopes to find new ways to improve the management of breast cancer and enhance the quality of life for those affected by this disease.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

The treatment plan includes several medications given through intravenous infusion or injection. Patients will receive paclitaxel and carboplatin as chemotherapy drugs, along with Herceptin and Perjeta which target the cancer cells. Some patients may also receive Kadcyla (trastuzumab emtansine), which combines Herceptin with another anti-cancer substance.

Throughout the study, doctors will use imaging tests to monitor how well the treatment is working. Based on these results, they may adjust the amount of chemotherapy given. The main goal is to see if this approach can effectively treat the cancer while potentially reducing the amount of chemotherapy needed. Patients will be monitored for at least three years after starting treatment to evaluate the long-term effectiveness of this approach.

The purpose of the study is to see if the combination of sacituzumab govitecan and pembrolizumab is more effective than sacituzumab govitecan alone. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 18 months, during which time participants will receive regular treatments and follow-up care to monitor their health and the effectiveness of the treatment.

Throughout the study, doctors will check for the absence of cancer in the breast and lymph nodes, which is known as a complete response. They will also track the participants’ health over three years to see if the cancer stays away. The study aims to improve treatment options for people with this type of breast cancer and to increase the chances of long-term health and recovery.

Participants in the study will receive these medications through infusions or injections over a period of time. The study will monitor how the cancer responds to these treatments and assess the long-term outcomes for the patients. The goal is to determine the effectiveness of the treatment in reducing the size of the tumor and improving the chances of successful surgery. The study will also look at the safety of the treatments and their impact on the quality of life of the participants.

Throughout the study, various aspects such as the clinical and radiological response of the cancer, the characteristics of the tumors, and the survival rates of the patients will be evaluated. The study will also consider the frequency of breast-conserving surgeries and the overall safety of the treatment regimen. This research is part of a larger effort to improve treatment strategies for patients with HER2-positive breast cancer.